BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the year ended December 31, 2011.
2011 Financial and Business Highlights
Revenue for 2011 increased 122% to a record $1.9 million, compared to $852,000 for 2010.
2011 Financial and Business Highlights
Revenue for 2011 increased 122% to a record $1.9 million, compared to $852,000 for 2010.
